Recent Advances in Thrombosis and Hemostasis: Part VI

Sam Schulman

doi:10.1055/s-0040-1715794

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2020; 46(08): 863-864
DOI: 10.1055/s-0040-1715794

Preface

Recent Advances in Thrombosis and Hemostasis: Part VI

Authors

Sam Schulman

¹Department of Medicine, Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada

²Department of Obstetrics and Gynecology, The First I.M. Sechenov Moscow State Medical University, Moscow, Russia

Abstract

Full Text

References

References
1 Khialani D, Rosendaal FR, van Hylckama Vlieg A. Hormonal contraceptives and the risk of venous thrombosis. Semin Thromb Hemost 2020; 46 (08) 865-871
2 Douxfils J, Maurimont L, Bouvy C. Oral contraceptives and venous thromboembolism: focus on testing that may enable prediction and assessment of the risk. Semin Thromb Hemost 2020; 46 (08) 872-886
3 Tang RB, Jing YY, Xu ZY. et al. New-onset atrial fibrillation and adverse in-hospital outcome in patients with acute pulmonary embolism. Semin Thromb Hemost 2020; 46 (08) 887-894
4 Tang RB, Xu ZY, Avula UMR. et al. Risk stratification for acute pulmonary embolism in patients with atrial fibrillation: role of CHADS₂ score. Semin Thromb Hemost 2017; 43 (08) 864-870
5 Anfinogenova YJ, Vasiltseva OY, Vrublevsky AV. et al. Right atrial thrombosis and pulmonary embolism: a narrative review. Semin Thromb Hemost 2020; 46 (08) 895-907
6 Bikdeli B, Catterjee S, Kirtane AJ. et al. Sulodexide versus control and the risk of thrombotic and hemorrhagic events: meta-analysis of randomized trials. Semin Thromb Hemost 2020; 46 (08) 908-918
7 Mian M, Sreedharan S, Limaye NS. et al. Research trends in anticoagulation therapy over the last 25 years. Semin Thromb Hemost 2020; 46 (08) 919-931
8 Abildgaard A, Madsen SA, Hvas AM. Dosage of anticoagulants in obesity: recommendations based on a systematic review. Semin Thromb Hemost 2020; 46 (08) 932-969
9 Russo V, Bottino R, Rago A. et al. Clinical performance of direct oral anticoagulants in real-world obese patients with atrial fibrillation. Semin Thromb Hemost 2020; 46 (08) 970-976
10 Beyer-Westendorf J, Schellong SM, Gerlach H. et al; SURPRISE Investigators. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. Lancet Haematol 2017; 4 (03) e105-e113
11 Kearon C, Carrier M, Gu C. et al. Rivaroxaban compared to placebo for the treatment of leg superficial vein thrombosis: a randomized trial. Semin Thromb Hemost 2020; 46 (08) 977-985
12 Schreuder M, Reitsma PH, Bos MHA. Reversal agents for the direct factor Xa inhibitors: biochemical mechanisms of current and newly emerging therapies. Semin Thromb Hemost 2020; 46 (08) 986-998
13 Cattaneo D, Formenti T, Gidaro A, Merlo A, Gervasoni C. Use of direct oral anticoagulants in people living with HIV: a single-center experience. Semin Thromb Hemost 2020; 46 (08) 999-1001
14 Udut VV, Udut EV, Kingma H, Demkin VP, Kotlovskaya LY, Shchetinin PP. Disturbances of hemostasis with vestibulo-atactic complications of chronic cerebral ischemia. Semin Thromb Hemost 2020; 46 (08) 1002-1006